It is now well established that obesity is a chronic inflammatory disorder. First proposed in pioneering studies from Hotamisligil and Spiegelman 1 more than a decade ago,
there is now convincing experimental evidence for the existence of an inflammatory link between obesity and the occurrence of the insulin resistance dyslipidemic syndrome commonly known as the 'metabolic syndrome'. An everincreasing number of molecules that are best known for their role in immune and inflammatory cells are now considered as key modulators of energy metabolism in insulin target tissues. In fact, several of those molecules (eg tumor necrosis factor (TNF)-a, interleukine (IL)-6 and IL-1) are expressed and secreted by fat cells in the expanded adipose tissue of obese subjects. Those immune/inflammatory mediators as well as adipose-specific cytokines (eg leptin and resistin) dubbed 'adipokines' exert their actions via a complex interplay of signal transduction mechanisms that we are just beginning to appreciate. The last few years have witnessed a burst of studies providing strong experimental and genetic support to the pathogenic role of some inflammatory pathways in the development of insulin resistance in obesity. The goal of this session of the symposium was to shed light on key inflammatory pathways thought to promote insulin resistance and the molecular mechanisms by which they are believed to interfere with insulin signaling. The use of salicylates for the treatment of diabetes mellitus was first reported more than a century ago and the glucoselowering action of aspirin was confirmed in the 1950s. Steven Shoelson presented recent experimental work supporting the hypothesis that high-dose aspirin exerts its beneficial effects through inhibition of the proinflammatory pathway Ikappa B kinase (IKK)/NF-kB, a known target of high-dose salicylates. In a series of elegant studies, Shoelson and colleagues have found that the IKK/NF-kB pathway is activated in insulin target tissues of obese insulin-resistant animals and that high-dose aspirin/salicylates improve insulin sensitivity and glucose tolerance in such animals. 2 To gain further genetic evidence for the role of the IKK/NFkB axis in obesity-linked insulin resistance, they have performed additional studies in heterozygous Ikkb þ /À mice fed a high-fat diet or crossed with obese ob/ob mice. In both models, a 50% decrease in the Ikkb gene led to reductions in blood glucose levels and improved insulin sensitivity. Highdose salicylates and heterozygous Ikkb gene deletion also protected against the insulin-resistant effects of lipid infusion in rats. Shoelson concluded his talk by proposing future directions that are intended to answer important questions such as the identification of target sites of IKK/NF-kBinduced insulin resistance. A more provocative question is whether salicylates should be reconsidered for the treatment of type 2 diabetic subjects. Recent data confirmed that highdose salicylates improve peripheral insulin action in diabetic patients, but additional studies using lower doses of salsalate, a less irritating head-to-tail dimer of salicylate, are currently underway to determine the efficacy of this drug in alleviating insulin resistance and improving glucose control. Salsalate may turn out to be an effective insulin sensitizer, and rejuvenate a 100-y-old concept that salicylates exert antidiabetic effects. Inflammatory cytokines also activate the MAP kinase pathway in several cell types. As reported by Gohkän Hotamisligil at this meeting, c-Jun N-terminal kinase (JNK) activity is elevated in tissues of dietary and genetic models of obesity. JNK1 but not JNK2 gene invalidation in mice protects from high-fat-induced obesity and insulin resistance. 3 It appears that JNK1 may cause insulin resistance by promoting serine phosphorylation of insulin receptor substrate-1 (IRS-1), which converts this protein into an inhibitor of insulin signaling. Indeed, JNK1 invalidation reduces IRS-1 phosphorylation on serine 307, a well-known site of heterologous inhibition of IRS-1 signaling. Genetic evidence linking increased JNK activity to human diabetes was also discussed. Indeed, loss-of-function mutations in JIP1, a natural inhibitor of JNK, causes type 2 diabetes in humans. Hotamisligil concluded his talk on some evolutionary concepts, alluding to the fat body of the fruit fly Drosophila melanogaster. This tissue concomitantly functions as a hepatic, adipose, and hematopoietic/immune organ and key proteins, including the fly equivalent of JNK, assume both metabolic and inflammatory functions. This offers a selective advantage in providing a strong immune response to overcome infections, but it brings about an equally strong metabolic response (eg insulin resistance), which, in the context of plenty, favors the expression of contemporary metabolic diseases such as diabetes and atherosclerosis. Proinflammatory cytokines may also cause insulin resistance by transcriptional mechanisms. Recent studies have shown that cytokine-induced expression of inducible nitric oxide synthase (iNOS) 4 and the suppressors of cytokine signaling family (SOCS), 5 can lead to impaired insulin signaling in muscle and fat tissues. In his talk, Emmanuel Van Obberghen summarized recent work from his group showing that SOCS3 is overexpressed in fat of murine models of acquired and genetic obesity and that exposure to TNF-a also induces SOCS3 expression in this tissue. Conversely, SOCS3 levels are decreased in the adipose tissue of ob/ob mice lacking TNF-a receptors. Hyperinsulinemia may also be involved in the negative action of SOCS3 on insulin signaling since insulin itself can promote its activation by tyrosine phosphorylation. SOCS3 may interfere with insulin signaling by competing with the ability of the insulin receptor to increase IRS-1 tyrosine phosphorylation and downstream signaling to PI 3-kinase, 5 or by favoring IRS-1/2 degradation through the ubiquitin-mediated degradation pathway as recently reported by White and colleagues. 6 Van
Obberghen also brought into perspective the fact that many insulin-resistant factors or pathways converge at the level of IRS proteins, either by uncoupling IRS-mediated downstream signals, and/or through promoting their degradation, at least in part by enhancing their serine phosphorylation. Yehiel Zick's presentation brought us even deeper into the signal transduction mechanisms leading to ser/thr phosphorylation of IRS proteins. He reminded us that ser/thr phosphorylation is not necessarily negative as the insulinresponsive protein kinase Akt/PKB also phosphorylates serines within the PTB domain of IRS-1 but that this protects from the action of protein tyrosine phosphatases and keeps IRS-1 in a tyrosine phosphorylated active state. 7 In contrast, other insulin-sensitive kinases, such as the mammalian target of rapamycin (mTOR), 8, 9 as well as atypical PKCz, 10 can also phosphorylate IRS-1 on serine residues and terminate insulin signaling at the level of PI 3-kinase. This may represent an efficient feedback regulatory mechanism of insulin signaling and the starting point may be located at the level of PI 3-kinase itself since its inhibitor, wortmannin, blocks the negative effects of the above IRS serine kinases. In inflammatory conditions such as obesity-linked diabetes, this feedback control loop may over-ride the normal activation of insulin signaling and thus promote insulin resistance. Interestingly, IKKb has been shown to be a substrate of PKCz and to be activated by a functional PKCz, leading to the hypothesis that IKKb may be a downstream mediator of PKCz-mediated inhibition of insulin signaling. This is supported by the observation that TNF-a activates both PKCz and IKKb. Zick concluded by asking an important question, that is, are the same or different pathways being utilized by insulin and inflammatory mediators to regulate the activity of IRS serine kinases? Clearly, overlapping pathways are likely to contribute to the modulation of ser/ thr phosphorylation of IRS proteins and the contribution of each of those pathways may well vary between individual target tissues. This symposium thus identified key signal transduction pathways activated by inflammatory mediators that can interfere with insulin receptor signaling in insulin target cells. A majority of these complex and inter-related pathways appear to converge at the level of IRS-1, by promoting its serine phosphorylation to mediate heterologous inhibition of IRS-1 signaling to counter-regulate the insulin response. The future challenge is to integrate reductionist models into reality and describe networks of signal transduction pathways in complex biosystems. A detailed knowledge of this complexity is a daunting task that will require a multifaceted approach, which is, nevertheless, necessary for the development of effective means for the treatment of insulin resistance, a pathognomonic syndrome in chronic metabolic disorders such as obesity, diabetes, and associated cardiovascular diseases.
